Literature DB >> 27070691

Deletion Mutations Keep Kinase Inhibitors in the Loop.

Daniel M Freed1, Jin H Park1, Ravi Radhakrishnan2, Mark A Lemmon3.   

Abstract

Effective clinical application of conformationally selective kinase inhibitors requires tailoring drug choice to the tumor's activating mutation(s). In this issue of Cancer Cell, Foster et al. (2016) describe how activating deletions in BRAF, EGFR, and HER2 cause primary resistance to common inhibitors, suggesting strategies for improved inhibitor selection.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27070691      PMCID： PMC5028821          DOI： 10.1016/j.ccell.2016.03.017

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  10 in total

Review 1.  Tumor adaptation and resistance to RAF inhibitors.

Authors:  Piro Lito; Neal Rosen; David B Solit
Journal:  Nat Med       Date:  2013-11       Impact factor: 53.440

Review 2.  A structural atlas of kinases inhibited by clinically approved drugs.

Authors:  Qi Wang; Julie A Zorn; John Kuriyan
Journal:  Methods Enzymol       Date:  2014       Impact factor: 1.600

3.  Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2.

Authors:  Scott A Foster; Daniel M Whalen; Ayşegül Özen; Matthew J Wongchenko; JianPing Yin; Ivana Yen; Gabriele Schaefer; John D Mayfield; Juliann Chmielecki; Philip J Stephens; Lee A Albacker; Yibing Yan; Kyung Song; Georgia Hatzivassiliou; Charles Eigenbrot; Christine Yu; Andrey S Shaw; Gerard Manning; Nicholas J Skelton; Sarah G Hymowitz; Shiva Malek
Journal:  Cancer Cell       Date:  2016-03-17       Impact factor: 31.743

4.  Crystal structure of a BRAF kinase domain monomer explains basis for allosteric regulation.

Authors:  Neroshan Thevakumaran; Hugo Lavoie; David A Critton; Andrew Tebben; Anne Marinier; Frank Sicheri; Marc Therrien
Journal:  Nat Struct Mol Biol       Date:  2014-12-01       Impact factor: 15.369

5.  ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma.

Authors:  Scott C Bresler; Daniel A Weiser; Peter J Huwe; Jin H Park; Kateryna Krytska; Hannah Ryles; Marci Laudenslager; Eric F Rappaport; Andrew C Wood; Patrick W McGrady; Michael D Hogarty; Wendy B London; Ravi Radhakrishnan; Mark A Lemmon; Yaël P Mossé
Journal:  Cancer Cell       Date:  2014-11-10       Impact factor: 31.743

6.  Activating HER2 mutations in HER2 gene amplification negative breast cancer.

Authors:  Ron Bose; Shyam M Kavuri; Adam C Searleman; Wei Shen; Dong Shen; Daniel C Koboldt; John Monsey; Nicholas Goel; Adam B Aronson; Shunqiang Li; Cynthia X Ma; Li Ding; Elaine R Mardis; Matthew J Ellis
Journal:  Cancer Discov       Date:  2012-12-07       Impact factor: 39.397

7.  Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.

Authors:  Shih-Hsun Chen; Youyan Zhang; Robert D Van Horn; Tinggui Yin; Sean Buchanan; Vipin Yadav; Igor Mochalkin; Swee Seong Wong; Yong Gang Yue; Lysiane Huber; Ilaria Conti; James R Henry; James J Starling; Gregory D Plowman; Sheng-Bin Peng
Journal:  Cancer Discov       Date:  2016-01-05       Impact factor: 39.397

8.  Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.

Authors:  Igor Vivanco; H Ian Robins; Daniel Rohle; Carl Campos; Christian Grommes; Phioanh Leia Nghiemphu; Sara Kubek; Barbara Oldrini; Milan G Chheda; Nicolas Yannuzzi; Hui Tao; Shaojun Zhu; Akio Iwanami; Daisuke Kuga; Julie Dang; Alicia Pedraza; Cameron W Brennan; Adriana Heguy; Linda M Liau; Frank Lieberman; W K Alfred Yung; Mark R Gilbert; David A Reardon; Jan Drappatz; Patrick Y Wen; Kathleen R Lamborn; Susan M Chang; Michael D Prados; Howard A Fine; Steve Horvath; Nian Wu; Andrew B Lassman; Lisa M DeAngelis; William H Yong; John G Kuhn; Paul S Mischel; Minesh P Mehta; Timothy F Cloughesy; Ingo K Mellinghoff
Journal:  Cancer Discov       Date:  2012-03-31       Impact factor: 39.397

Review 9.  Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms.

Authors:  Natalia Jura; Xuewu Zhang; Nicholas F Endres; Markus A Seeliger; Thomas Schindler; John Kuriyan
Journal:  Mol Cell       Date:  2011-04-08       Impact factor: 17.970

10.  Guidelines for investigating causality of sequence variants in human disease.

Authors:  D G MacArthur; T A Manolio; D P Dimmock; H L Rehm; J Shendure; G R Abecasis; D R Adams; R B Altman; S E Antonarakis; E A Ashley; J C Barrett; L G Biesecker; D F Conrad; G M Cooper; N J Cox; M J Daly; M B Gerstein; D B Goldstein; J N Hirschhorn; S M Leal; L A Pennacchio; J A Stamatoyannopoulos; S R Sunyaev; D Valle; B F Voight; W Winckler; C Gunter
Journal:  Nature       Date:  2014-04-24       Impact factor: 49.962
  10 in total
  1 in total

1.  Exploring Molecular Mechanisms of Paradoxical Activation in the BRAF Kinase Dimers: Atomistic Simulations of Conformational Dynamics and Modeling of Allosteric Communication Networks and Signaling Pathways.

Authors:  Amanda Tse; Gennady M Verkhivker
Journal:  PLoS One       Date:  2016-11-18       Impact factor: 3.240
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.